Lilly asks FDA to not allow lone use of COVID-19 drug bamlanivimab

Eli Lilly and Co (LLY.N) said it had requested for cancellation of the U.S. authorization granted to its COVID-19 antibody, bamlanivimab, which will now be used in combination with another to achieve greater efficacy against emerging virus variants.